RxDoctor Payments DataLook up a doctor →

Matthew Kuhn, NP

Acute Care · Pinehurst, NCNPI 1306434147

Payments from drug & device makers

$15,770in general payments, 2019–2025

Across 524 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$2K
  • Altathera Pharmaceuticals LLC$2K
  • Boehringer Ingelheim$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • AstraZeneca$1K
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$1,2008%
  • Speaking & faculty fees$190%
  • Travel & lodging$8796%
  • Food & beverage$13,59186%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,770 in reported general payments places this provider in the 95th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Medicare billing

Part B allowed, 2024
$78,435
Medicare patients
368
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$134,440
XareltoRivaroxaban89$65,651
JardianceEmpagliflozin86$57,613
Dofetilide199$22,406
EntrestoSacubitril/Valsartan20$19,363
FarxigaDapagliflozin Propanediol21$13,087
VerquvoVericiguat11$8,091
InpefaSotagliflozin11$6,257
Metoprolol Succinate293$2,952
SotalolSotalol Hcl148$1,758
Losartan Potassium136$1,462
Carvedilol258$1,258
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,213
Flecainide Acetate33$1,090
Potassium Chloride117$1,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$458$134,440195 claims
Johnson & JohnsonXarelto$871$65,65189 claims
Boehringer IngelheimJardiance$1,464$57,61386 claims
NovartisEntresto$703$19,36320 claims
AstraZenecaFarxiga$1,070$13,08721 claims
MerckVerquvo$422$8,09111 claims
Lexicon Pharmaceuticals, Inc.Inpefa$140$6,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 acute care providers in North Carolina.

Other acute care in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →